Rahulp4444
The recombinant vaccines market is poised for robust growth, projected to reach a promising revenue of US$2,440.6 million by the year 2028, supported by a commendable Compound Annual Growth Rate (CAGR) of 6.1%. This signifies a strong and steady upward trajectory for the market, reflecting increasing demand and advancements in the field of recombinant vaccines.